CINCINNATI--(BUSINESS WIRE)--In response to reports of a shortage of one C1 esterase inhibitor (C1-INH) product on the market, BioRx affirmed today that its supply of Berinert® (C1 esterase inhibitor, human) remains strong and can immediately accommodate increased demand. The statement was in response to publicly reported production delays affecting the only other commercially available C1-INH product. C1-INH products are FDA-approved for the treatment of hereditary angioedema (HAE).
